FDA Advisory Panel Recommends Approval Of Remicade Knockoff An FDA advisory panel approved a knockoff arthritis drug called Remsima from Pfizer Inc. and Celltrion Inc. The drug is the biosimilar version of Amgen's Remicade, which has brought billions of profits for the company. by Rina Marie Doctor